That's what this article is suggesting....this might explain the change in the FA number.  I'm not paying for the full ariticle, there's enough food for thought in the snippet provided....specifically that the phase III trial may not be robust enough, that's my takeaway.

http://www.biopharminsight.com/resverlogix%E2%80%99s-apabetalone-diabetic-population-target-strikes-expert-debate-phase-iii-cvd-trial